CheckMate -025, a Pivotal Phase III Opdivo Renal Cell Cancer Trial, Stopped Early
July 20, 2015 at 08:01 AM EDT
Bristol-Myers Squibb Company (NYSE: BMY) today announced that an open-label, randomized Phase III study evaluating Opdivo (nivolumab) ...
